Sanofi granted European marketing authorization for Cerdelga in Gaucher disease

French drug major Sanofi (Euronext: SAN) and its subsidiary Genzyme have been granted marketing authorization by the European Commission for Cerdelga (eliglustat) in Gaucher disease type 1.

The drug was approved by the US Food and Drug Administration in August 2014, and is under review by other health regulatory authorities around the world. Cerdelga is expected to be commercially available in the EU from 2015.

Cerdelga adds to Genzyme’s rare disease drug portfolio, and will complement Cerezyme (imiglucerase for injection), the standard of care for patients with Gaucher disease type 1, which is administered through intravenous infusions. The capsule formulation would provide an improved administration regimen for patients.